查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589797

勃起功能障礙藥物市場：按藥物、給藥方法、分銷管道分類 - 全球預測 2025-2030

Erectile Dysfunction Drugs Market by Drug (Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra)), Mode of Administration (Injections, Oral, Topical), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年勃起功能障礙藥物市場價值為24.1億美元，預計到2024年將達到25.9億美元，複合年成長率為7.41%，預計到2030年將達到39.8億美元。

勃起功能障礙 (ED) 藥物的市場範圍包括旨在治療男性 ED 的藥物，ED 的定義是無法獲得或維持足以進行性交的勃起。此類別包括但不限於 5 型磷酸二酯酶抑制劑，例如Sildenafil（威而鋼）、他達拉非（犀利士）和伐地那非（艾力達）。人口老化、糖尿病和心血管疾病等慢性疾病的增加，以及壓力和肥胖等生活方式因素影響的 ED 盛行率的增加，推動了對此類藥物的需求。最終用途部分包括使用或開立這些藥物的醫院、診所和家庭護理機構。

主要市場統計
基準年[2023] 24.1億美元
預測年份 [2024] 25.9億美元
預測年份 [2030] 39.8億美元
複合年成長率（%） 7.41%

市場成長受到諸如 ED 作為醫療狀況的認知和接受程度提高、藥物配方的進步以及臨床試驗中強大的治療藥物管道等因素的影響。新的治療機會在於開發副作用較少的下一代治療劑、開發長效製劑以及開發局部應用和注射等腸胃外給藥系統。新興國家的潛在成長進一步加劇了這種情況，這些國家生活方式的改變增加了 ED 的發病率，使其成為一個開拓的市場。

然而，存在一些限制和挑戰，例如嚴格的監管要求、潛在的副作用以及草藥補充品和真空勃起裝置等替代療法的存在，這些可能會影響藥物干預措施的市場滲透。創新和研究機會包括探索個人化醫療方法，例如 ED 治療反應性的遺傳標記以及遠端醫療與患者診斷和處方服務的整合。了解市場動態需要識別影響患者接受治療意願的障礙，例如 ED 恥辱感。總體而言，透過專注於研發、策略夥伴關係和推廣計劃，市場參與者可以利用這些趨勢並實現永續成長。

市場動態：揭示快速發展的勃起功能障礙藥物市場的關鍵市場洞察

供需的動態交互作用正在改變勃起功能障礙藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 老年族群中勃起功能障礙患者數量不斷增加
    • 久坐的生活方式和文明病的發生率增加
    • 非學名藥的普及和OTC ED藥物的獲取便利性
  • 市場限制因素
    • 與勃起功能障礙藥物相關的副作用
  • 市場機會
    • ED 藥物的進步和新產品上市數量的增加
    • 研究和發展的重點是開發勃起功能障礙的有效治療方法
  • 市場挑戰
    • 具有成本效益的假藥的可用性

波特五力：駕馭勃起功能障礙藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解勃起功能障礙藥物市場的外部影響

外部宏觀環境因素在塑造勃起功能障礙治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解勃起功能障礙治療藥物市場的競爭狀況

勃起功能障礙藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣勃起功能障礙治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估勃起功能障礙治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製勃起功能障礙治療藥物市場的成功之路

對於希望加強在全球市場的影響力的公司來說，勃起功能障礙藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人勃起功能障礙增加
      • 久坐的生活方式和文明病的發生率增加
      • 非學名藥的普及和非處方 ED 治療的便利性
    • 抑制因素
      • 與勃起功能障礙藥物相關的副作用
    • 機會
      • ED 治療藥物的進步和新產品的推出不斷增加
      • 研究和開發的重點是開發有效的治療方法和治療勃起功能障礙的方法
    • 任務
      • 具有成本效益的假藥的可用性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 勃起功能障礙治療藥物市場（依藥物）

  • 阿伐那非（Stendra）
  • Muse栓劑（Alprostadil）
  • Sildenafil（威而鋼）
  • 他達拉非（犀利士）
  • 伐地那非（艾力達，Staxyn）

第7章依管理方式分類的勃起功能障礙治療藥物市場

  • 注射
  • 口服
  • 話題

第8章勃起功能障礙治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美和南美的勃起功能障礙藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區勃起功能障礙藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的勃起功能障礙藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Adamed Sp. z oo
  • Bayer AG
  • Cipla Limited
  • Dr. Reddys Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • Futura Medical PLC
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • SK Chemicals Co. Ltd.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vivus, Inc.
Product Code: MRR-4348D129FAF4

The Erectile Dysfunction Drugs Market was valued at USD 2.41 billion in 2023, expected to reach USD 2.59 billion in 2024, and is projected to grow at a CAGR of 7.41%, to USD 3.98 billion by 2030.

The market scope for erectile dysfunction (ED) drugs encompasses pharmaceuticals aimed at treating males with ED, a condition defined as the persistent inability to achieve or maintain an erection sufficient for sexual intercourse. This category includes but is not limited to phosphodiesterase type 5 inhibitors like sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). The necessity for such medications is driven by the increasing prevalence of ED, influenced by aging populations, rising chronic health conditions like diabetes and cardiovascular diseases, and lifestyle factors such as stress and obesity. Applications primarily revolve around enhancing erectile function to improve patient quality of life, while end-use segments include hospitals, clinics, and home care settings where these drugs are administered or prescribed.

KEY MARKET STATISTICS
Base Year [2023] USD 2.41 billion
Estimated Year [2024] USD 2.59 billion
Forecast Year [2030] USD 3.98 billion
CAGR (%) 7.41%

Market growth is influenced by factors such as increased awareness and acceptance of ED as a medical condition, advancements in drug formulations, and a robust pipeline of therapies under clinical trials. Emerging opportunities lie in developing next-generation treatment options with fewer side effects, long-acting formulations, and non-oral delivery systems, such as topical applications or injections. The landscape is further expanding with potential growth in emerging economies where lifestyle pattern shifts lead to higher ED incidence rates, representing untapped markets.

However, limitations and challenges include strict regulatory requirements, potential side effects, and the presence of alternative therapies such as herbal supplements or vacuum erectile devices, which may affect the market uptake of pharmaceutical interventions. Innovation and research opportunities exist in exploring personalized medicine approaches, such as genetic markers for ED treatment responsiveness, and the integration of telemedicine in patient diagnosis and prescription services to enhance reach and adherence. Understanding market dynamics requires identifying barriers like stigmatization of ED, which affects patient willingness to seek treatment. Overall, a keen focus on R&D, strategic partnerships, and outreach programs can help market players capitalize on these trends for sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Erectile Dysfunction Drugs Market

The Erectile Dysfunction Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase cases of erectile dysfunction among geriatric population
    • Rising adoption of a sedentary lifestyle and incidence of lifestyle diseases
    • Prevalence of non generic drugs and easy availability of OTC ED drugs
  • Market Restraints
    • Side effects associated with the erectile dysfunction drugs
  • Market Opportunities
    • Increasing advancements and new product launches of ED drugs
    • R&D focused on developments of effective therapies and treatments for erectile dysfunction
  • Market Challenges
    • Availability of cost-effective counterfeit drugs

Porter's Five Forces: A Strategic Tool for Navigating the Erectile Dysfunction Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Erectile Dysfunction Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Erectile Dysfunction Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Erectile Dysfunction Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Erectile Dysfunction Drugs Market

A detailed market share analysis in the Erectile Dysfunction Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Erectile Dysfunction Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Erectile Dysfunction Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Erectile Dysfunction Drugs Market

A strategic analysis of the Erectile Dysfunction Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Erectile Dysfunction Drugs Market, highlighting leading vendors and their innovative profiles. These include Adamed Sp. z o.o., Bayer AG, Cipla Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, Endo International PLC, Futura Medical PLC, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novartis International AG, Pfizer Inc., S.K. Chemicals Co. Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vivus, Inc..

Market Segmentation & Coverage

This research report categorizes the Erectile Dysfunction Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra), Tadalafil (Cialis), and Vardenafil (Levitra, Staxyn).
  • Based on Mode of Administration, market is studied across Injections, Oral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase cases of erectile dysfunction among geriatric population
      • 5.1.1.2. Rising adoption of a sedentary lifestyle and incidence of lifestyle diseases
      • 5.1.1.3. Prevalence of non generic drugs and easy availability of OTC ED drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the erectile dysfunction drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing advancements and new product launches of ED drugs
      • 5.1.3.2. R&D focused on developments of effective therapies and treatments for erectile dysfunction
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of cost-effective counterfeit drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Erectile Dysfunction Drugs Market, by Drug

  • 6.1. Introduction
  • 6.2. Avanafil (Stendra)
  • 6.3. Muse Suppository (Alprostadil)
  • 6.4. Sildenafil (Viagra)
  • 6.5. Tadalafil (Cialis)
  • 6.6. Vardenafil (Levitra, Staxyn)

7. Erectile Dysfunction Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injections
  • 7.3. Oral
  • 7.4. Topical

8. Erectile Dysfunction Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Erectile Dysfunction Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Erectile Dysfunction Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Erectile Dysfunction Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adamed Sp. z o.o.
  • 2. Bayer AG
  • 3. Cipla Limited
  • 4. Dr. Reddys Laboratories Ltd.
  • 5. Eli Lilly and Company
  • 6. Endo International PLC
  • 7. Futura Medical PLC
  • 8. GlaxoSmithKline PLC
  • 9. Johnson & Johnson Services, Inc.
  • 10. Novartis International AG
  • 11. Pfizer Inc.
  • 12. S.K. Chemicals Co. Ltd.
  • 13. Sanofi S.A.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Vivus, Inc.

LIST OF FIGURES

  • FIGURE 1. ERECTILE DYSFUNCTION DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ERECTILE DYSFUNCTION DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ERECTILE DYSFUNCTION DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023